Hepatic protection by 16, 16-dimethyl prostaglandin E2 (DMPG) against acute aflatoxin B1-induced injury in the rat.
Studies were conducted to assess the possible protective action of 16,16-dimethyl prostaglandin E2 (DMPG) against acute aflatoxin B1 (AFB1) induced hepatic injury in the rat. Evaluation of liver damage by histopathologic techniques and clinical chemistry indicated that hepatic necrosis was ameliorated by treatment with DMPG even though binding of radiolabeled (3H)-AFB1 to hepatic DNA was unaffected by this prostaglandin. However, DMPG did not protect rats against AFB1-induced mortality. These data suggest that hepatic protection by DMPG was due to mechanisms other than an interference with the activation or hepatic binding of AFB1.
Rush
B D
BD
Diabetes and GI Diseases, Upjohn Company, Kalamazoo, Michigan 49001.
Wilkinson
K F
KF
Nichols
N M
NM
Ochoa
R
R
Brunden
M N
MN
Ruwart
M J
MJ
D015064:16,16-Dimethylprostaglandin E2 / Q000494:pharmacology*; D016604:Aflatoxin B1; D000348:Aflatoxins / Q000633:toxicity*; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control*; D004247:DNA / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D008099:Liver / Q000378:metabolism; D008297:Male; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D000348:Aflatoxins; D011459:Prostaglandins E, Synthetic; D004247:DNA; D016604:Aflatoxin B1; D015064:16,16-Dimethylprostaglandin E2